Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
The target demographic will be those between the ages of 30 and 65 years
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Subscribe To Our Newsletter & Stay Updated
